cefpodoxime and Plasmacytoma

cefpodoxime has been researched along with Plasmacytoma* in 1 studies

Other Studies

1 other study(ies) available for cefpodoxime and Plasmacytoma

Article	Year
Pyridinylimidazole inhibitors of Tie2 kinase. Bioorganic & medicinal chemistry letters, 2007, Sep-01, Volume: 17, Issue:17 This communication details the evolution of the screening lead SB-203580, a known CSBP/p38 kinase inhibitor, into a potent and selective Tie2 tyrosine kinase inhibitor. The optimized compound 5 showed efficacy in an in vivo model of angiogenesis and a MOPC-315 plasmacytoma xenograft model. Topics: Animals; Cell Line, Tumor; Drug Design; Enzyme Inhibitors; Humans; Imidazoles; Inhibitory Concentration 50; Mice; Models, Chemical; Models, Molecular; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Plasmacytoma; Pyridines; Receptor, TIE-2	2007

Article

Year

Pyridinylimidazole inhibitors of Tie2 kinase.

Bioorganic & medicinal chemistry letters, 2007, Sep-01, Volume: 17, Issue:17

This communication details the evolution of the screening lead SB-203580, a known CSBP/p38 kinase inhibitor, into a potent and selective Tie2 tyrosine kinase inhibitor. The optimized compound 5 showed efficacy in an in vivo model of angiogenesis and a MOPC-315 plasmacytoma xenograft model.

Topics: Animals; Cell Line, Tumor; Drug Design; Enzyme Inhibitors; Humans; Imidazoles; Inhibitory Concentration 50; Mice; Models, Chemical; Models, Molecular; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Plasmacytoma; Pyridines; Receptor, TIE-2

2007